September 2013

Many people in the medical world question the safety of selective serotonin reuptake inhibitors and other serotenergic antidepressants when used during pregnancy.  Over 40 million Americans today suffer from depression, anxiety, or other related mental health issues.  There is an ongoing debate about the safety of these drugs and if they possess long term health risks for both the mother and the fetus.  The Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy, conducted a study titled “Serotonin Reuptake Inhibitors and Other Serotonergic/Noradrenergic Antidepressants During Pregnancy: A Review”, where their objective was to address concerns associated with the use of SSRIs and other serotonergic antidepressants during pregnancy.

Case reports, case series, and meta analyses were identified through searches of MEDLINE and EMBASE to gather information for this study.  Specific search terms were used, such as Fluoxetine, Paroxetine, Sertraline, Citalopram, escitalopram, in utero exposure, and neonatal complications.  Major malformations such as cardiac defects have been associated with Paroxetine when used during pregnancy.

Author Tuccori M. from the above study states “Significant associations between maternal exposure to SSRIs and both persistent pulmonary hypertension of the newborn and a self-limiting neonatal behavioral syndrome have been reported in a number of recent original studies and meta-analyses. Some studies have suggested a relationship between the use of SSRIs or other serotonergic/noradrenergic antidepressants and the occurrence of miscarriage, although these studies had methodologic limitations that affected the strength of the data.”

There is only weak evidence for the association between utero exposure to SSRIs and alterations in neurobehavioral development.  SSRIs should be used with caution during pregnancy, and many doctors recommend follow up of infants exposed to these drugs during development.  Here is another paper about Paroxetine in the first trimester and the prevalence of congenital malformations.

As a result of the volume of research coming out showing a connection between SSRIs and birth defects, a number of SSRI birth defect lawsuits, particularly Paxil birth defect lawsuits, have been filed.

If you or a loved one used SSRIs during pregnancy and your child was born with a birth defect, please do not hesitate to contact our team of Paxil® birth defects lawyers at the information below for a free, no-obligation case consultation.  We will be here to help every step of the way.

(855) 452-5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

Author S. Raimondi from the European Institute of Oncology in Milan, Italy, wrote an article titled “Pancreatic Cancer in Chronic Pancreatitis; Aetiology, Incidence, and Early Detection”.  Chronic pancreatitis, acute pancreatitis, and pancreatic cancer are primarily responsible for most of the negative effects of exocrine pancreatic disease.  The pancreas is a flat gland found in the upper abdomen, behind the stomach.  The primary function of this gland is to produce digestive enzymes and hormones that regulate sugar levels in the human body.  Chronic pancreatitis may cause severe and life threatening complications and may be associated with an elevated risk for pancreatic cancer.

Raimondi states “Glandular damage from recurrent bouts of acute pancreatitis can lead to irreversible changes characteristic of chronic pancreatitis. In recent decades accumulating evidence has defined longstanding pre-existing chronic pancreatitis as a strong risk factor for pancreatic cancer. The lag period between diagnosis of chronic pancreatitis and pancreatic cancer is usually one or two decades: pancreatitis appearing a year or two before the diagnosis of pancreatic cancer is often the result of tumour-related ductal obstruction.”  Rare types of pancreatitis with early onset have the greatest risk factor in developing pancreatic cancer.  These types of pancreatitis are hereditary pancreatitis and tropical pancreatitis.

A positive correlation between chronic pancreatitis and pancreatic cancer has been found: about five percent of patients with chronic pancreatitis will develop pancreatic cancer.  Screening is the best way for early detection of pancreatic cancer, but development of more sophisticated screening procedures are needed.  Before better methods of screening are developed, it is not recommend  that patients with chronic pancreatitis be screened.

Recently, a number of diabetes drugs such as Victoza, Byetta, and Januvia (used in GLP-1 therapy for type two diabetes) have been associated with a dramatically increased risk for pancreatitis and pancreatic cancer.  As these potentially deadly side-effects were not made clear by the manufacturers in light of the publication of many papers showing connections between GLP-1 therapy and cancer, a number of Victoza lawsuits, Byetta lawsuits, and Januvia lawsuits have been filed.

If you or a loved one used Januvia, Byetta, Victoza, or another GLP-1 therapy drug for type two diabetes and suffered from pancreatitis or pancreatic cancer, you may be entitled to significant financial compensation for the injuries you have sustained by no fault of your own.

For a free, no-obligation case consultation, contact our team of Victoza lawyers, Byetta lawyers, and Januvia lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.

(855) 452-5529

justinian@dangerousdrugs.us

Our Byetta Lawsuit / Victoza Lawsuits / Januvia Lawsuit Information page is a great place to start if you have any questions about GLP-1 therapy drugs and diabetes drug lawsuits.

Women with pre-existing psychiatric illnesses are considered have an increased risk for depressive episodes during pregnancy.  Due to this elevated risk, many times it is necessary to start a pharmacological treatment of depression during these times.  The aim of a review written by the Department of Mental Health, ASL Salerno 1, District n. 4, Cava de’ Tirreni (Salerno), Italy, titled “The Safety of Newer Antidepressants in Pregnancy and Breastfeeding” was to examine the effects on the fetus through placenta and maternal milk to the following drugs: fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram, mirtazapine, venlafaxine, reboxetine and bupropion.  There are limitations to some of the studies done on this subject, but older selective serotonin reuptake inhibitors seem to be without teratogenic risks.  There may be possible consequences related to exposure to SSRIs from placenta and breastmilk, but these findings are still controversial.

However, reports do exist that show an association between placental exposure to SSRI and adverse effects on neonatal adaptation.  Author Gentile S. is quoted saying “In addition, the information on both teratogenic and functional teratogenic risks associated with exposure to bupropion, mirtazapine and reboxetine is incomplete or absent; at present, these compounds should not be used as first-line agents in the pharmacological treatment of depression in pregnancy and breastfeeding. Untreated depression is not without its own risks since mothers affected by depression have a negative impact on the emotional development of their children and major depression, especially when complicated by a delusional component, may lead to the mother attempting suicide and infanticide.”

Mothers who are not mentally stable pose other risks for their children, so taking medications during pregnancy may be the best option.  It is the job of your doctor to explain the risks of prenatal exposure to your child as well as the risks of untreated depression.

Due to the fact that many women who used SSRIs during pregnancy were not made aware of the risk for birth defects and poor neonatal adaptation associated with SSRIs, a number of Prozac® birth defects lawsuits, Paxil® birth defects lawsuits, Effexor® birth defects lawsuits, Celexa® birth defects lawsuits, Zoloft® birth defects lawsuits have been filed.  Many other SSRIs have also been associated with birth defects and spark lawsuits all over the world.

If you or a loved one used SSRIs during pregnancy and your child was born with a birth defect, you may be entitled to financial compensation through an SSRI birth defects lawsuit.  For a free, no-obligation case consultation, please do not hesitate to contact our team of SSRI birth defect lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.

(855) 452-5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

Some studies and anecdotal reports have shown that pancreatitis may cause an individual to develop, or be at a higher risk to develop pancreatic cancer.  Pancreatitis is defined as inflammation in the pancreas.  The pancreas produces enzymes that help with digestion as well as produce hormones that regulate the way your body processes sugar.  Pancreatitis can appear suddenly and last for a few days, or can inflict an individual for years, this type is called chronic pancreatitis.

While the human body may be able to fight some, mild cases of pancreatitis, chronic pancreatitis may cause serious and often times life threatening complications.  There is limited information on this subject, and more research needs to be done to determine the magnitude of the relationship between these two diseases.  A multicenter historical cohort study was done by author Albert B. Lowenfels, from the New England Journal of Medicine, titled “Pancreatitis and the Risk of Pancreatic Cancer”, to further explore the relationship between pancreatitis and pancreatic cancer.  2,015 patients with chronic pancreatitis were used for this study.  Information was obtained from clinical centers in six countries.  From the 2,015 subjects used in this study, 56 cancers were identified, there was a mean follow of 7.4 years.  The number of cases of cancer calculated from country specific incidence data was 2.13, which yielded a standardized incidence ratio of 26.3.  Data was adjusted for age and sex.

Author Albert B. Lowenfels states “For subjects with a minimum of two or five years of follow-up, the respective standardized incidence ratios were 16.5 (95 percent confidence interval, 11.1 to 23.7) and 14.4 (95 percent confidence interval, 8.5 to 22.8).”  Cumulative risk of pancreatic cancer in subjects who were followed for at least 2 years showed a steady increase in pancreatic cancer.  10 and 20 years after being diagnosed of pancreatitis, patients showed 1.8 percent chance of developing pancreatic cancer.  People who are diagnosed with chronic pancreatitis have a significantly higher risk of pancreatic cancer, and these findings seem to be independent of sex, country, and type of pancreatitis.

Recently, a number of GLP-1 therapy drugs used to treat type two diabetes drugs have been linked to pancreatitis and pancreatic cancer.  Currently, much of the research only shows that drugs like Victoza, Byetta, and Januvia are associated with pancreatitis, but studies like the one summarized above show us that if one suffers from pancreatitis, the risk for pancreatic cancer is 16 times higher than if one did not have pancreatitis.  Here is a link to a study showing GLP-1 therapy drugs are associated with cancer.

Due to the fact that the manufacturers of many of these drugs have failed to warn of the risk for pancreatitis and pancreatic cancer, a number of Byetta lawsuits, Victoza lawsuits, Januvia lawsuits, and other GLP-1 therapy drug lawsuits have been filed.

If you or a loved one used a GLP-1 therapy drug such as Victoza, Januvia, and Byetta and suffered from either pancreatitis or pancreatic cancer, you may be entitled to significant financial compensation.  For more information, please do not hesitate to contact our team of Victoza lawyers, Januvia lawyers, and Byetta lawyers at the information provided below.  We have the resources, skills, and experience required to win the justice you deserve, even from the largest of pharmaceutical manufacturers.

(855) 452-5529

justinian@dangersoudrugs.us

Our Byetta Lawsuit / Victoza Lawsuits / Januvia Lawsuit Information page is a great place to start if you have any questions about GLP-1 therapy drugs and diabetes drug lawsui

Long term spatial and egocentric learning and memory deficits and serotonin reductions were shown to be connected with the use of methylenedioxymethamphetamine.  5-HT is a neurotrophic factor that may influence neurogenesis, synaptogenesis, and target field-  organization during brain development.  The objective of a study done by the  Division of Child Neurology, Department of Pediatrics at Cincinnati Children’s Research Foundation and University of Cincinnati College of Medicine in Cincinnati, OH, titled “Cognitive Impairments From Developmental Exposure to Serotonergic Drugs: Citalopram and MDMA” was to determine the harmful effects of such drugs on the developing fetus, and any long term effects they may possess.  MDMA was given to rats during a period of development that approximates human third trimester brain development, was found to be associated with 50 percent reduction in 5-HT during treatment and 20 percent reductions with adults.

Author TL Schaefer from the above study states “To determine whether the 5-HT reduction is responsible for the cognitive deficits, we used citalopram (Cit) pretreatment to inhibit the effects of MDMA on 5-HT reuptake in a companion study. Cit attenuated MDMA-induced 5-HT reductions by 50% (Schaefer et al., 2012). Here we tested whether Cit (5 or 7.5 mg/kg × 2/d) pretreatment attenuates the cognitive effects of MDMA. Within each litter, different offspring were treated on PD11-20 with saline (Sal) + MDMA, Cit + MDMA, Cit + Sal or Sal + Sal.”

Celexa pretreatment did not improve spatial nor egocentric learning/memory.  It was shown however, that Cit plus Sal did produce spatial and egocentric learning deficits as bad as those caused by Sal plus MDMA.  Little data is available about selective serotonin reuptake inhibitors and their harmful effects during developmental exposure.  These findings shows that there is a connection between cognitive deficits from developmental exposure.

If you used an SSRI such as Celexa during pregnancy and your child had a negative birth outcome or developmental problems, you may be entitled to significant financial compensation through a Celexa birth defects lawsuit.  Contact our team of Celexa® birth defects lawyers for a free, no-obligation case consultation.

(855) 452-5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

Serotonin reuptake inhibitors such as Escitalopram are prescribed for depression and anxiety.  Over 40 million Americans suffer from depression or anxiety, leading these to be the most common mental illness in the United States today.  The Department of Motherisk Program, The Hospital for Sick Children, Toronto, Ontario, Canada, conducted a study titled “Pregnancy Outcomes Following Use of Escitalporam: A Prospective Comparative Cohort Study”, where their objective was to determine if escitalopram is associated with an increased risk for major malformations or other unwanted outcomes following use in pregnancy.

Pregnancy outcomes in women exposed to escitalopram, other antidepressants, and nonteratogenic exposures were analyzed and compared the outcomes of each.  Author Klieger-Grossmann C. states “ Among the escitalopram exposures were 172 (81%) live births, 32 (15%) spontaneous abortions, 6 (2.8%) therapeutic abortions, 3 stillbirths (1.7%), and 3 major malformations (1.7%). The only significant differences among groups was the rate of low birth weight (<2500 g) and overall mean birth weight (P = .225).”  It was shown that spontaneous abortion rates were higher in both antidepressant groups when compared with the control groups.

Escitalopram was associated with lower rates of live births, lower overall birth rates, and increased rates of low birth rates.  Compared to the control group, spontaneous abortion rates were doubled in both antidepressant groups.  There was not a clear connection made between escitalopram and an increased risk for major malformations.  However, there seems to be an increase in frequency of low birth weight.  Furthermore, the study confirmed previous findings that higher rates of spontaneous abortions are more common with exposure to antidepressants.

If you or a loved one used SSRI during pregnancy and your child had a negative birth outcome, your family may be entitled to significant financial compensation from the manufacturer of the SSRIs used.  In recent years, SSRI birth defect lawsuits have been filed around the world because SSRI drug manufacturers have failed time and again to warn women of the risks associated with their products.

For more information or a free, no-obligation case consultation, please do not hesitate to contact our team of SSRI birth defect lawyers.  We have the experience, resources, and skills required to win the justice you deserve.

(855) 452-5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.  Call today and see how we can help!

Antidepressant drugs are commonly used during pregnancy.  Fetus Exposure to these drugs may have some unwanted side effects.   The Department of Histology and Embryology, 3rd Faculty of Medicine, Charles University, in Czech Republic, conducted a study called “Antidepressant Drug Exposure During Pregnancy.  CZTIS small prospective study”, where they investigated the risk assessment of SSRI exposure and possible increase of inborn defects, neonatal abstinence syndrome and cognitive ability or behavioral defects associated with SSRI’s.

Author Manakova E. states “In our study, we prospectively followed groups of pregnancies in years 2002-2009, that were exposed to SSRI. As control group we used 1) women exposed to new atypical antidepressant and anti-psychotics – APD (risperidone, mirtazapine, venlafaxine, trazodone, aripiprazole, ziprasidone, olanzapine), 2) women exposed to nonteratogenic drugs and 3) the general population according to Institute of Health Informations and Statistics.”  The study enrolled 43 women exposed to SSRI and 37 women exposed to new psychotropic drugs.  SSRI exposure was associated with polytherapy.  Citalopram, escitalopram, and setraline were the SSRI’s most commonly used.  The results showed significantly higher rates of elective terminations in the group given SSRI’s.  Higher frequency of abortions was found in the APD group.  Overall frequency of malformations was not found to be varied, being in all groups in expected range.  Manakova E. concludes by stating, “We confirmed that SSRI exposure during pregnancy was not associated with the higher risk of major malformation. However, number of cases was low and did not allow the statistical treatment with higher power.”

Due to the fact that many SSRI manufacturers have time and again failed to warn users of the risk for birth defects associated with their products, a number of SSRI birth defects lawsuits have been filed.  If you or a loved one used SSRIs during pregnancy and your child was born with a birth defect, you may be entitled to significant financial compensation for the injuries you family sustained by no fault of your own.

For more information, please feel free to contact our team of SSRI birth defect lawyers at the information below.  We have the experience, resources, and skills required to win the justice you deserve.

(855) 452-5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

Studies have shown that 3 percent of pregnant women are treated with antidepressants during gestation.  This percentage is found to slightly increase after delivery of the baby, from 5-7 percent.  Fluoxetine, paroxetine, sertraline, citalopram, and venlafaxine (VENF) are all serotonin reuptake inhibitors or serotonin and noradrenaline reuptake inhibitors that are most commonly prescribed during pregnancy.  There is little information about these drugs and their potential harmful effects because experimental studies with these drugs are rare, despite the drug being categorized as  drug level C by the FDA.  The aim of a study done by the Institute of Experimental Pharmacology & Toxicology, Slovak Academy of Sciences, titled “Effect of Prenatal Administration of Venlafaxine on Postnatal Development of Rat Offspring”, was to investigate the effect of prenatal administration of VENF on early postnatal development of rat offspring.

Dubovicky writes “Pregnant female Wistar rats were treated with VENF from day 15 to 20 of gestation at the doses of 7.5, 37.5 and 70 mg/kg. Females were allowed to spontaneously deliver their pups. After delivery the pups were inspected for viability, gross malformation and they were weighed on day 0, 4 and 21 post partum. On day 21 post partum, the pups were killed, brains were removed from the skulls and blood samples were collected for biochemical assay (proteins, glucose-GOD, glucose-HEX, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase and total antioxidant status).”  The study showed that Effexor exposure resulted in maternal intoxication that lead to decreased body weight gain of pregnant females.  No morphological alterations were observed in the rat offspring, and no selected biochemical variables were determined.

This study may be used in an Effexor lawsuit to demonstrate that the manufacturer of Effexor knew, or should have know, that Effexor is associated with negative birth outcomes.  If you or a loved one used Effexor during pregnancy and your child had a negative birth outcome, you may be entitled to significant financial compensation for injuries caused to your baby by no fault of your own.

For a free, no-obligation case consultation, contact our team of Effexor® birth defects lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452-5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

The objectives for a study done by the  Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, titled “Selective Serotonin reuptake Inhibitors During Pregnancy and Risk of Persistent Pulmonary Hypertension in the Newborn: Population Based Cohort Study from the Five Nordic Countries”, was to determine if maternal use of selective serotonin reuptake inhibitors increase the risk of pulmonary hypertension in newborns.  This experiment was a population based cohort study that collected information from the National Health Registers.  More than 1.6 million infants born after week 33 were used in this study.

Author H. Kieler from the above study states, “Risks of persistent pulmonary hypertension of the newborn associated with early and late exposure to SSRIs during pregnancy and adjusted for important maternal and pregnancy characteristics. Comparisons were made between infants exposed and not exposed to SSRIs.”  It was shown that   11,014 women who had been given an SSRI later than gestational week 20 were associated with an increased risk of persistent pulmonary hypertension in the newborns.  There was an increased risk found for persistent pulmonary hypertension in newborn for each specific SSRI and the risks were similar in magnitude for all of them.  Exposure to an SSRI before gestation week 8 was shown to slightly increase risks for malformations.

Kieler concludes with “The risk of persistent pulmonary hypertension of the newborn is low, but use of SSRIs in late pregnancy increases that risk more than twofold. The increased risk seems to be a class effect.”  There is little information available about the risks of antidepressants taken during pregnancy.  There is a high demand for more studies to be done in order for the medical community to have a sound understanding regarding all the risks involved.

With the publication of many studies such as this showing the danger of SSRI use during pregnancy, a number of SSRI birth defect lawsuits have been filed.  If you or a loved one used SSRIs during pregnancy and your child was born with a birth defect, you may be entitled to significant financial compensation for the injuries your family has sustained by no fault of your own.  For more information, please do not hesitate to contact our team of SSRI birth defects lawyers  at the information provided below.  We have the skills, resources, and experience required to win the justice you deserve.

(855) 452-5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

Selective serotonin reuptake inhibitor drugs (SSRIs) are commonly prescribed to people suffering from depression.  This often includes pregnant women, due to the increased risk of complications when a pregnant mother is suffering from untreated depression.  Unfortunately, the medications prescribed to pregnant women with depression have also been associated with malformations of the fetus.  Many studies have been conducted to quantify the association between SSRI use during pregnancy and the risk of malformation of the fetus.

Several of these studies have been summarized and published in the journal Prescrire International, and one of them, titled “SSRI antidepressants and birth defects” in part reviews several other research papers on the topic.  One study referenced by the authors of that paper claimed “Between 20% and 30% of newborns exposed to selective serotonin reuptake inhibitor antidepressants (SSRIs) toward the end of gestation have disorders such as agitation, abnormal muscle tone and suction, seizures and hyponatraemia.”

A Danish study estimated that the congenital malformation risk of taking SSRIs during pregnancy, relative to the general population, was quantified to be “1.4 (95% CI 1.1-1.9) and the relative risk of cardiac malformation was 1.6 (95% CI 1.0-2.6).”  This means that the risk for a birth defect in your child if you use SSRIs in pregnancy is 40% higher than if you do not use SSRIs, and that the risk for heart defects is 60% higher than if one were not to use SSRIs during gestation.

An American study that compared the risks of paroxetine to all other SSRIs reported that “the estimated relative risk for all congenital malformations was 2.20 (95% CI 1.34-3.63), and the estimated relative risk of cardiovascular malformations was 2.08 (95% CI 1.03-4.23)”.  Essentially, this study claimed that paroxetine was twice as likely to result in some kind of fetal malformation.  A Swedish study reported similar results, concluding that paroxetine was associated with a 2.22 (95% CI 1.39-3.55) increased likelihood of cardiac malformations relative to the general population.

Lastly, a case-control study estimated the “relative risk of omphalocele was 3.0 with all SSRIs (95% CI 1.4 to 6.1), and the estimated relative risk of craniosynostosis was 1.8 (95% CI 1.0-3.2).”  Omphalocele is a condition characterized by malformations in the abdomen, while craniosynostosis is a malformation of the skull.

The report concludes, “all SSRIs have been implicated in a possible increase in the risk of congenital malformations, but the most worrisome evidence concerns paroxetine.” (Paroxetine is the main active ingredient in Paxil.)

With the publication of so many studies like this, many birth defect lawsuits have been filed, including a number of Paxil birth defect lawsuits.  If you or a loved one used Paxil during pregnancy (or another SSRI) and your child was born with a birth defect, please do not hesitate to contact our team of Paxil® birth defects lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.

(855) 452-5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.